A review of treatments targeting DNA-repair gene defects in metastatic castration resistant prostate cancer

Prostate cancer is the most common cancer in men. About 6% of those diagnosed will develop metastatic disease. Unfortunately, metastatic prostate cancer is fatal. Prostate cancer can be castration sensitive or castration resistant. Many treatments have been shown to improve progression free survival...

Descripción completa

Detalles Bibliográficos
Autores principales: Maslov, Diana V., Sember, Quinne, Cham, Jason, Bhangoo, Munveer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046303/
https://www.ncbi.nlm.nih.gov/pubmed/36998466
http://dx.doi.org/10.3389/fonc.2023.1150777
_version_ 1785013639147683840
author Maslov, Diana V.
Sember, Quinne
Cham, Jason
Bhangoo, Munveer
author_facet Maslov, Diana V.
Sember, Quinne
Cham, Jason
Bhangoo, Munveer
author_sort Maslov, Diana V.
collection PubMed
description Prostate cancer is the most common cancer in men. About 6% of those diagnosed will develop metastatic disease. Unfortunately, metastatic prostate cancer is fatal. Prostate cancer can be castration sensitive or castration resistant. Many treatments have been shown to improve progression free survival and overall survival in metastatic castration resistant prostate cancer (mCRPC). In recent years, studies have been exploring targeting mutations in the DNA Damage Repair (DDR) response that may amplify oncogenes. In this paper, we aim to discuss DDR, new approved targeted therapies, and the most recent clinical trials in the setting of metastatic CRPC.
format Online
Article
Text
id pubmed-10046303
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100463032023-03-29 A review of treatments targeting DNA-repair gene defects in metastatic castration resistant prostate cancer Maslov, Diana V. Sember, Quinne Cham, Jason Bhangoo, Munveer Front Oncol Oncology Prostate cancer is the most common cancer in men. About 6% of those diagnosed will develop metastatic disease. Unfortunately, metastatic prostate cancer is fatal. Prostate cancer can be castration sensitive or castration resistant. Many treatments have been shown to improve progression free survival and overall survival in metastatic castration resistant prostate cancer (mCRPC). In recent years, studies have been exploring targeting mutations in the DNA Damage Repair (DDR) response that may amplify oncogenes. In this paper, we aim to discuss DDR, new approved targeted therapies, and the most recent clinical trials in the setting of metastatic CRPC. Frontiers Media S.A. 2023-03-14 /pmc/articles/PMC10046303/ /pubmed/36998466 http://dx.doi.org/10.3389/fonc.2023.1150777 Text en Copyright © 2023 Maslov, Sember, Cham and Bhangoo https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Maslov, Diana V.
Sember, Quinne
Cham, Jason
Bhangoo, Munveer
A review of treatments targeting DNA-repair gene defects in metastatic castration resistant prostate cancer
title A review of treatments targeting DNA-repair gene defects in metastatic castration resistant prostate cancer
title_full A review of treatments targeting DNA-repair gene defects in metastatic castration resistant prostate cancer
title_fullStr A review of treatments targeting DNA-repair gene defects in metastatic castration resistant prostate cancer
title_full_unstemmed A review of treatments targeting DNA-repair gene defects in metastatic castration resistant prostate cancer
title_short A review of treatments targeting DNA-repair gene defects in metastatic castration resistant prostate cancer
title_sort review of treatments targeting dna-repair gene defects in metastatic castration resistant prostate cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046303/
https://www.ncbi.nlm.nih.gov/pubmed/36998466
http://dx.doi.org/10.3389/fonc.2023.1150777
work_keys_str_mv AT maslovdianav areviewoftreatmentstargetingdnarepairgenedefectsinmetastaticcastrationresistantprostatecancer
AT semberquinne areviewoftreatmentstargetingdnarepairgenedefectsinmetastaticcastrationresistantprostatecancer
AT chamjason areviewoftreatmentstargetingdnarepairgenedefectsinmetastaticcastrationresistantprostatecancer
AT bhangoomunveer areviewoftreatmentstargetingdnarepairgenedefectsinmetastaticcastrationresistantprostatecancer
AT maslovdianav reviewoftreatmentstargetingdnarepairgenedefectsinmetastaticcastrationresistantprostatecancer
AT semberquinne reviewoftreatmentstargetingdnarepairgenedefectsinmetastaticcastrationresistantprostatecancer
AT chamjason reviewoftreatmentstargetingdnarepairgenedefectsinmetastaticcastrationresistantprostatecancer
AT bhangoomunveer reviewoftreatmentstargetingdnarepairgenedefectsinmetastaticcastrationresistantprostatecancer

Ejemplares similares